Novartis

Novartis Wins Two Prestigious Prix Galien Foundation Awards

Gleevec® recognized as “Discovery of the Decade” for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
Press Release

Basel, November 2, 2016 /3BL Media/ – Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.

Top Selling Pharmaceutical Companies Ranked According to Diversity in Executive Leadership

Press Release

HOUSTON, October 18, 2016 /3BL Media/ - The National Diversity Council is proud to present “Leading While Diverse: The Case for Diversity in Corporate Governance,” a comprehensive research report ranking top pharmaceutical companies based on their diversity in executive positions and boards of directors. The reputation of multinational pharmaceutical companies is currently one of the lowest, second only to health insurance companies.

Time to Talk about Partnerships for Access to Medicines

Opinion of Harald Nusser on www.sharedvalue.org
Blog

Access to healthcare is making controversial headlines these days as the report of the High-Level Panel on Access to Medicines set up by the Secretary-General of the United Nations was just released. We need to move away from ideological disputes about intellectual property and focus on how we can help patients receive the treatments they need now.

Any solution to the access challenge needs to consider the complex factors that affect access in developing countries. It would indeed be misleading and counter-productive to focus the access debate on patents. (...)

Novel Novartis Compound Shows Potential as Effective Therapy for Treating Drug Resistant Malaria

Results published in the New England Journal of Medicine
Press Release
  • Results published in the New England Journal of Medicine demonstrate that
    KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites

  • KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines

Malaria Experts and African Leaders Challenged to Maintain the Momentum and Win the Race for Malaria Elimination

Summary: 
  • National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control
     
  • Event brings together delegates from 33 African countries to accelerate malaria elimination efforts
     
  • Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million treatments distributed since 2001, including over 300 million dispersible pediatric treatments
Press Release
  • National Malaria Control Program best practice sharing workshop takes place in Senegal, which has made great strides in malaria control
     
  • Event brings together delegates from 33 African countries to accelerate malaria elimination efforts
     
  • Novartis Malaria Initiative celebrates treatment delivery milestone, with more than 800 million treatments distributed since 2001, including over 300 million dispersible pediatric treatments

Preparing to Stop Drug-Resistant Malaria

By David Reddy, CEO, Medicines for Malaria Venture and Jürgen Brokatzky-Geiger, Global Head of Corporate Responsibility, Novartis
Blog

No child should ever die from a mosquito bite. Yet, today, in an era of extraordinary medical advancement, a child dies of mosquito-borne malaria every two minutes. Last year, this agonizing blood disease caused by the malaria parasite claimed nearly half a million lives—most of them children.

Novartis Expands Partnership with Medicines for Malaria Venture to Develop Next-Generation Antimalarial Treatment

Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation
Summary: 

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment 

  • Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation

  • KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle

  • Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies

Press Release

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment 

  • Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation

  • KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite’s lifecycle

  • Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies

BeatRHD! Experts from Across the World Meet in Mexico to Talk About Heart Diseases

Article

From June 4-7 Novartis scientists participate in the World Congress of Cardiology & Cardiovascular Health (WCC) in Mexico. This Congress brings together thousands of heart health professionals from around the world. One of the key topics is rheumatic heart disease (RHD).

Africa Has a New Health Challenge, and We Need a Plan to Fight It

Blog written by Harald Nusser, Global Head Novartis Access
Blog

While the headlines might focus on Ebola or yellow fever, Africa is slowly winning the fight against infectious diseases. They will remain a challenge for decades to come, but the real threat of the future is expected to come from elsewhere: non-communicable diseases (NCDs) like diabetes, cardiovascular disease and cancer.

Novartis Foundation and Partners Launch Innovative Hypertension Program in Vietnam

Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
Summary: 
  • Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation 

  • Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers

  • Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control

  • Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact 

Press Release
  • Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation 

  • Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers

  • Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control

  • Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact 

Pages

Subscribe to Novartis